NR4A1 and breast cancer: Breast cancers in BRCA-mutation carriers and BRCA-wild type patients differ from those in women with sporadic breast cancers in terms of age at presentation, hormone receptor and c-erbB2 status, type of local and systemic adjuvant therapy received and second primary incidence.